Gene Biotherapeutics IncOver The Counter Market:CRXM
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gene Biotherapeutics Inc | 60.0 | 0.0x | --- |
Arno Therapeutics Inc | 14.8K | 0.0x | --- |
Rebus Holdings Inc | 3.2K | 0.0x | --- |
Refocus Group Inc | 20.0 | 0.0x | --- |
Easton Pharmaceuticals Inc | 1.3K | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Company Information
Gene Biotherapeutics Inc. is a clinical-stage biotechnology company, which is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.
Contact Information
- Headquarters
- 11230 Sorrento Valley Rd, Suite 220SAN DIEGO, CA, United States 92121
- Phone
- 858-414-1477
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Financial Officer, Secretary
- James Grainer
- President, Chief Executive Officer, Treasurer
- Christopher Reinhard
- Chief Operating Officer
- Lois Chandler
- Chief Scientific Officer
- Ronald Shebuski
- Director
- Kaushik Vyas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 64.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 7.46 |
EPS | $-0.04 |
Book Value | $-0.10 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
